Inventor · Sunnyvale, CA, US

Paul R. Hinton

22Patents
12h-index
35Co-inventors
81Inventor score

Filing activity: Jun 2, 1995 → Aug 27, 2018

Most-cited inventions

PatentTitleAreaCited byStatus
US7217797B2 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis Chemistry; Metallurgy 140 Expired
US6218149A Antibodies having modified carbohydrate content and methods of preparation and use Chemistry; Metallurgy 111 Expired
US7217798B2 Alteration of Fc-fusion protein serum half-lives by mutagenesis Chemistry; Metallurgy 80 Expired
US7915388B2 Interleukin-13 binding proteins Emerging Cross-Sectional Technologies 79 Active
US7034121B2 Antibodies against CTLA4 Chemistry; Metallurgy 73 Expired
US7361740B2 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis Chemistry; Metallurgy 58 Expired
US7700739B2 IL-12/p40 binding proteins Chemistry; Metallurgy 47 Active
US7320790B2 Humanized antibodies Emerging Cross-Sectional Technologies 36 Expired
US7122185B2 Anti-CCR5 antibody Chemistry; Metallurgy 23 Expired
US7365168B2 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis Chemistry; Metallurgy 20 Expired
US8629257B2 IL-12/p40 binding proteins Chemistry; Metallurgy 18 Active
US9592293B2 Interleukin-13 binding proteins Emerging Cross-Sectional Technologies 16 Active
US7666419B2 Anti-CCR5 antibody Chemistry; Metallurgy 12 Active
US7223393B2 Amphiregulin antibodies and their use to treat cancer and psoriasis Physics 8 Expired
US7732570B2 Alteration of Fc-fusion protein serum half-lives by mutagenesis Chemistry; Metallurgy 7 Active
US7442777B2 Cytotoxicity mediation of cells evidencing surface expression of CD63 Physics 6 Expired
US8604177B2 Interleukin-13 binding proteins Emerging Cross-Sectional Technologies 3 Active
US10086076B2 Interleukin-13 binding proteins Emerging Cross-Sectional Technologies 2 Active
US7851600B2 Anti-CCR5 antibody Chemistry; Metallurgy 1 Active
US11344621B2 Interleukin-13 binding proteins Emerging Cross-Sectional Technologies 0 Active
US10150814B2 Fc variants with improved complement activation Chemistry; Metallurgy 0 Active
US8624007B2 Alteration of Fc-fusion protein serum half-lives by mutagenesis Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.